mobocertinib succinate · Takeda Pharms Usa · NDA 215310
Exkivity
Earliest generic entry, as listed
13 May 2035
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 10227342, US 9796712.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10227342 | drug substance, drug product, use U-3220 · sets the listed date | 13 May 2035 |
| US 9796712 | drug substance, drug product · sets the listed date | 13 May 2035 |
Exclusivities · 1 unexpired
| ODE-374 | orphan drug (7 years) | 15 Sep 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 215310 · 001 · RLD · discontinued | capsule, oral | EQ 40MG BASE | 13 May 2035 |
Expired or delisted (1)
- NCE · 15 Sep 2026